5 月 24 日,CDE 官网显示,药明巨诺“瑞基奥仑赛注射液”递交一项新适应症上市申请。Insight 数据库显示,这是瑞基奥仑赛在国内申报的第 4 项上市申请,推测用于治疗一线治疗失败后不适合大剂量化疗(HDCT)和自体干细胞移植(ASCT)的成人复发或难治性侵袭性 B 细胞非霍奇金淋巴瘤(r/r B-NHL)患者。截图来源:CDE 官网瑞基奥仑赛是一款靶向 CD19 的自体 CAR-T ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.